Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan for prevention of PCI-related myocardial injury
ChiCTR2200062051Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of levosimendan in coronary arteriosclerosis (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: High-sensitivity cardiac troponin T. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
levosimendan
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2200062051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062051.